Skip to main content
Veterinary Medicines

NEO-VAKY AD

Suspended
  • Aujeszky's disease virus, strain Bartha K61, Live

Product identification

Medicine name:
NEO-VAKY AD
Active substance:
  • Aujeszky's disease virus, strain Bartha K61, Live
Target species:
  • Pig
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Aujeszky's disease virus, strain Bartha K61, Live
    5.50
    cell culture infective dose 50
    /
    2.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI09AD01
Authorisation status:
  • Suspended
Authorised in:
  • Spain
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Laboratorios Ovejero S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Ovejero S.A.
Responsible authority:
  • Spanish Agency For Medicines And Health Products
Authorisation number:
  • 3349 ESP
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 7/03/2024

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 7/03/2024

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 7/03/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."